You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

199 Results
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
May 2025
Regimen
Cancer Type:
Gastrointestinal, 
Gastric / Stomach
Intent: Palliative
Mar 2025
Regimen
Cancer Type:
Gastrointestinal, 
Gastric / Stomach
Intent: Palliative
Mar 2025
Regimen
Cancer Type:
Gastrointestinal, 
Gastric / Stomach
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Mar 2025
Regimen
Cancer Type:
Gastrointestinal, 
Gastric / Stomach
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Mar 2025
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Adjuvant, Palliative
Funding:
ODB - General Benefit
    degarelix
Feb 2025
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
ODB - General Benefit
    dexamethasone
May 2025
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - In Combination with Pomalidomide and Dexamethasone for Previously Treated Multiple Myeloma
ODB - General Benefit
    dexamethasone
Exceptional Access Program
    pomalidomide - In combination with bortezomib and dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma, based on criteria
Apr 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Feb 2025
Regimen
Cancer Type:
Lung, 
Mesothelioma (Pleural)
Intent: Palliative
May 2025
Regimen
Intent: Neoadjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer
May 2025
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Adjuvant, Palliative
Feb 2025

Pages